Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better Together
Abstract
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. They do not work on the same target, however. While Lecanemab targets pathologic amyloid protofibrils, Donanemab targets the amyloid plaque itself intracranially. In theory, they can be administered together, as combination therapy, to produce an augmented effect. Research of the feasibility of such a combination will require bringing together competing pharmaceutical companies, which can only happen by setting a national agenda bringing together academia, pharma, the government and advocacy groups.
Fields of Study & Subjects
Alzheimer's disease research and treatments
Dementia and Cognitive Impairment Research
Neuroinflammation and Neurodegeneration Mechanisms
Publication details
- Journal / source
- Alzheimer Disease & Associated Disorders
- Volume
- 40
- Issue
- 1
- Pages
- 65–66
- Publication date
- 1 January 2026
- Language
- EN